Immix Biopharma IncNASDAQ:IMMX
- LAST PRICE1.9600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 1.9600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMMX |
|---|---|---|
| 09:32 ET | 662 | 2.11 |
| 09:41 ET | 240 | 2.1 |
| 09:48 ET | 1000 | 2.0994 |
| 10:19 ET | 400 | 2.075 |
| 10:24 ET | 150 | 2.115 |
| 10:28 ET | 649 | 2.1 |
| 10:32 ET | 637 | 2.109 |
| 10:33 ET | 15042 | 2 |
| 10:39 ET | 100 | 2.025 |
| 10:42 ET | 200 | 2.025 |
| 10:46 ET | 100 | 2.025 |
| 10:50 ET | 200 | 2.02 |
| 10:53 ET | 200 | 2.02 |
| 11:00 ET | 3504 | 2.035 |
| 11:18 ET | 1000 | 2.0487 |
| 11:20 ET | 617 | 2.02 |
| 11:45 ET | 216 | 2.0106 |
| 11:47 ET | 470 | 2.01 |
| 11:54 ET | 100 | 2.02 |
| 11:56 ET | 300 | 2.02 |
| 12:14 ET | 4573 | 1.97 |
| 12:16 ET | 805 | 1.9636 |
| 12:23 ET | 300 | 1.96 |
| 12:27 ET | 300 | 1.96 |
| 12:34 ET | 400 | 1.98 |
| 12:36 ET | 25537 | 1.925 |
| 12:38 ET | 100 | 1.925 |
| 12:39 ET | 3729 | 1.9 |
| 12:41 ET | 985 | 1.92 |
| 12:43 ET | 156 | 1.9 |
| 12:45 ET | 200 | 1.9114 |
| 12:50 ET | 500 | 1.9197 |
| 12:54 ET | 1100 | 1.92 |
| 12:56 ET | 100 | 1.91 |
| 12:57 ET | 10200 | 1.92 |
| 12:59 ET | 437 | 1.94 |
| 01:01 ET | 4640 | 1.9338 |
| 01:03 ET | 200 | 1.9493 |
| 01:06 ET | 700 | 1.932 |
| 01:08 ET | 200 | 1.935 |
| 01:10 ET | 300 | 1.9361 |
| 01:12 ET | 600 | 1.94 |
| 01:17 ET | 100 | 1.9499 |
| 01:19 ET | 15102 | 1.98 |
| 01:21 ET | 900 | 1.9677 |
| 01:24 ET | 100 | 1.9928 |
| 01:26 ET | 850 | 1.98 |
| 01:32 ET | 2012 | 1.9796 |
| 01:35 ET | 900 | 1.95 |
| 01:37 ET | 905 | 1.9535 |
| 01:42 ET | 200 | 1.94 |
| 01:51 ET | 200 | 1.9485 |
| 01:57 ET | 200 | 1.9498 |
| 02:00 ET | 100 | 1.9201 |
| 02:15 ET | 1000 | 1.965 |
| 02:18 ET | 200 | 1.98 |
| 02:27 ET | 200 | 1.97 |
| 02:31 ET | 200 | 1.97 |
| 02:36 ET | 502 | 1.9989 |
| 02:49 ET | 500 | 1.985 |
| 03:34 ET | 1000 | 1.99 |
| 03:45 ET | 200 | 2 |
| 03:48 ET | 100 | 2.01 |
| 03:50 ET | 1481 | 2.01 |
| 03:52 ET | 200 | 2 |
| 03:54 ET | 12112 | 1.99 |
| 03:57 ET | 612 | 1.975 |
| 03:59 ET | 900 | 1.96 |
Jul 1, 2024
DJ Immix Biopharma Initiated at Buy by HC Wainwright & Co., from 6:20AM ET on Monday Jul 01, 2024 by Dow Jones
6:20AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 17, 2024
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum, from 9:35AM ET on Monday Jun 17, 2024 by Dow Jones
9:35AM ET on Monday Jun 17, 2024 by Dow JonesImmix Biopharma to Present at the Stifel 2024 Cell Therapy Forum, from 9:35AM ET on Monday Jun 17, 2024 by Dow Jones
9:35AM ET on Monday Jun 17, 2024 by Dow Jones
Jun 10, 2024
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships, from 8:30AM ET on Monday Jun 10, 2024 by Dow Jones
8:30AM ET on Monday Jun 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immix Biopharma Inc | 51.8M | -2.1x | --- |
OKYO Pharma Ltd | 41.0M | -0.1x | --- |
Mural Oncology PLC | 51.6M | -0.3x | --- |
ARCA Biopharma Inc | 52.4M | -8.7x | --- |
Reneo Pharmaceuticals Inc | 50.5M | -0.7x | --- |
Rallybio Corp | 49.7M | -0.6x | --- |
Company Information
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Contact Information
- Headquarters
- 11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
- Phone
- 310-651-8041
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Ilya Rachman
- Scientific Co-Founder
- Vladimir Torchilin
- Chief Financial Officer, Director
- Gabriel Morris
- Head - Chemistry, Manufacturing, and Control
- Nandan Oza
- Acting Chief Medical Officer, Head - Clinical Development
- Graham Ross
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $51.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 26.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.93 |
Book Value | $0.82 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
